Status:
COMPLETED
Extension Study of 1.0mg Dose Letrozole Therapy in Postmenopausal Patients With Breast Cancer
Lead Sponsor:
Novartis Pharmaceuticals
Collaborating Sponsors:
Chugai Pharmaceutical
Conditions:
Postmenopausal Women With Advanced Breast Cancer
Eligibility:
FEMALE
20-74 years
Phase:
PHASE2
Brief Summary
\- To investigate the safety of letrozole monotherapy at a dose 1.0 mg/day or fadrozole monotherapy at a dose 2.0mg in Japanese postmenopausal patients with advanced breast cancer which participated i...
Eligibility Criteria
Inclusion
- \- Patients which participated in double blind study
Exclusion
- Patients with intolerable toxicity.
- Patients which confirmed progressive disease during double blind study.
- Patients which have received concurrent anti-cancer therapy during double blind study.
Key Trial Info
Start Date :
December 1 1999
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
Estimated Enrollment :
17 Patients enrolled
Trial Details
Trial ID
NCT00247663
Start Date
December 1 1999
Last Update
April 19 2012
Active Locations (10)
Enter a location and click search to find clinical trials sorted by distance.
1
Novartis Investigative Site
Kashiwa, Chiba, Japan, 277-8577
2
Novartis Investigative Site
Amagasaki, Hyōgo, Japan, 660-8511
3
Novartis Investigative Site
Hamamatsu, Shizuoka, Japan, 430-8558
4
Novartis Investigative Site
Chuo-Ku, Tokyo, Japan, 104-0045